Stimulated whole saliva secretion following rituximab treatment in patients with primary Sjögren's syndrome. Stimulated whole saliva secretion (SWS) at baseline and at 5 and 12 weeks following rituximab treatment in 14 patients with primary Sjögren's syndrome; an increase in saliva secretion occurred only in patients (n = 9) with baseline SWS >0.10 ml/minute and not in patients (n = 5) with baseline secretion <0.10 ml/minute. SWS consisted of submandibular and sublingual (SM/SL) salivary secretion. Reprinted with permission from .
Kallenberg et al. Arthritis Research & Therapy 2011 13:205 doi:10.1186/ar3234